These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 29374852

  • 1. Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma.
    Hamy AS, Lam GT, Laas E, Darrigues L, Balezeau T, Guerin J, Livartowski A, Sadacca B, Pierga JY, Vincent-Salomon A, Coussy F, Becette V, Bonsang-Kitzis H, Rouzier R, Feron JG, Benchimol G, Laé M, Reyal F.
    Breast Cancer Res Treat; 2018 Jun; 169(2):295-304. PubMed ID: 29374852
    [Abstract] [Full Text] [Related]

  • 2. Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy.
    Liu YL, Saraf A, Lee SM, Zhong X, Hibshoosh H, Kalinsky K, Connolly EP.
    Breast Cancer Res Treat; 2016 Jun; 157(3):555-64. PubMed ID: 27225388
    [Abstract] [Full Text] [Related]

  • 3. Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy.
    Ryu YJ, Kang SJ, Cho JS, Yoon JH, Park MH.
    Medicine (Baltimore); 2018 Jul; 97(30):e11647. PubMed ID: 30045313
    [Abstract] [Full Text] [Related]

  • 4. Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy.
    Hamy AS, Darrigues L, Laas E, De Croze D, Topciu L, Lam GT, Evrevin C, Rozette S, Laot L, Lerebours F, Pierga JY, Osdoit M, Faron M, Feron JG, Laé M, Reyal F.
    PLoS One; 2020 Jul; 15(6):e0234191. PubMed ID: 32579551
    [Abstract] [Full Text] [Related]

  • 5. Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Survival.
    Orsaria P, Grasso A, Ippolito E, Pantano F, Sammarra M, Altomare C, Cagli B, Costa F, Perrone G, Soponaru G, Caggiati L, Vanni G, Buonomo OC, Altomare V.
    Anticancer Res; 2021 May; 41(5):2697-2709. PubMed ID: 33952501
    [Abstract] [Full Text] [Related]

  • 6. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U, Cabello C, Ramalho SOB, Zeferino LC.
    BMC Cancer; 2019 Jun 17; 19(1):601. PubMed ID: 31208353
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX, Qin QH, Yang WP, Mo QG, Wei CY.
    Int J Clin Exp Pathol; 2014 Jun 17; 7(10):6862-70. PubMed ID: 25400769
    [Abstract] [Full Text] [Related]

  • 8. Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems.
    Choi M, Park YH, Ahn JS, Im YH, Nam SJ, Cho SY, Cho EY.
    Breast Cancer Res Treat; 2016 Dec 17; 160(3):475-489. PubMed ID: 27730423
    [Abstract] [Full Text] [Related]

  • 9. Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore.
    Laas E, Labrosse J, Hamy AS, Benchimol G, de Croze D, Feron JG, Coussy F, Balezeau T, Guerin J, Lae M, Pierga JY, Reyal F.
    Br J Cancer; 2021 Apr 17; 124(8):1421-1427. PubMed ID: 33558711
    [Abstract] [Full Text] [Related]

  • 10. Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
    Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC.
    Oncologist; 2017 May 17; 22(5):526-534. PubMed ID: 28377466
    [Abstract] [Full Text] [Related]

  • 11. Predictors of lymphovascular invasion in estrogen receptor positive/Her-2 negative breast cancer patients treated with neoadjuvant chemotherapy.
    Çavdar E, İriağaç Y.
    Turk J Med Sci; 2022 Aug 17; 52(4):1111-1117. PubMed ID: 36326379
    [Abstract] [Full Text] [Related]

  • 12. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy.
    Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P, Schoenberg MP, Lerner SP, Sagalowsky AI.
    J Clin Oncol; 2005 Sep 20; 23(27):6533-9. PubMed ID: 16116151
    [Abstract] [Full Text] [Related]

  • 13. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H, Chaltier L, Belin L, Savignoni A, Rouzier R, Sablin MP, Lerebours F, Bidard FC, Cottu P, Sastre-Garau X, Laé M, Pierga JY, Reyal F.
    PLoS One; 2015 Sep 20; 10(12):e0144359. PubMed ID: 26684197
    [Abstract] [Full Text] [Related]

  • 14. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F, Erdem GU, Sahin S, Aytekin A, Yuce D, Sever AR, Babacan T, Ates O, Ozisik Y, Altundag K.
    Breast; 2017 Apr 20; 32():237-244. PubMed ID: 27318645
    [Abstract] [Full Text] [Related]

  • 15. Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy.
    Truong PT, Yong CM, Abnousi F, Lee J, Kader HA, Hayashi A, Olivotto IA.
    J Am Coll Surg; 2005 Jun 20; 200(6):912-21. PubMed ID: 15922205
    [Abstract] [Full Text] [Related]

  • 16. Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy.
    Kantor O, Laws A, Pastorello RG, King C, Wong S, Dey T, Schnitt S, King TA, Mittendorf EA.
    Ann Surg Oncol; 2021 Nov 20; 28(12):7347-7355. PubMed ID: 33956276
    [Abstract] [Full Text] [Related]

  • 17. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
    Miglietta F, Dieci MV, Tsvetkova V, Griguolo G, Vernaci G, Menichetti A, Faggioni G, Giarratano T, Mioranza E, Genovesi E, Cumerlato E, Bottosso M, Saibene T, Michieletto S, Lo Mele M, Conte P, Guarneri V.
    Oncologist; 2020 Sep 20; 25(9):e1355-e1362. PubMed ID: 32618068
    [Abstract] [Full Text] [Related]

  • 18. The role of lymph node metastasis in the systemic dissemination of breast cancer.
    Nathanson SD, Kwon D, Kapke A, Alford SH, Chitale D.
    Ann Surg Oncol; 2009 Dec 20; 16(12):3396-405. PubMed ID: 19657697
    [Abstract] [Full Text] [Related]

  • 19. Lymphovascular Invasion Increases the Risk of Nodal and Distant Recurrence in Node-Negative Stage I-IIA Non-Small-Cell Lung Cancer.
    Sung SY, Kwak YK, Lee SW, Jo IY, Park JK, Kim KS, Lee KY, Kim YS.
    Oncology; 2018 Dec 20; 95(3):156-162. PubMed ID: 29847825
    [Abstract] [Full Text] [Related]

  • 20. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
    Roland CL, Yang AD, Katz MH, Chatterjee D, Wang H, Lin H, Vauthey JN, Pisters PW, Varadhachary GR, Wolff RA, Crane CH, Lee JE, Fleming JB.
    Ann Surg Oncol; 2015 Apr 20; 22(4):1168-75. PubMed ID: 25352267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.